
McKesson Corporation company profile
$1102.80+2.39%Close 13 Nov 2026 · Market value $127.9B
About McKesson Corporation
McKesson Corporation is a diversified healthcare services company that distributes pharmaceuticals, medical-surgical supplies, and related products and services to biopharma companies, care providers, pharmacies, manufacturers, and governments. Its operations are organized into four reportable segments: North American Pharmaceutical, which distributes branded, generic, specialty, biosimilar, and over-the-counter drugs in the United States and Canada; Oncology & Multispecialty, which supports oncology and specialty physician practices; Prescription Technology Solutions, which provides medication access and benefit technology services; and Medical-Surgical Solutions, which supplies non-acute and alternate-site healthcare providers in the U.S. The company also operates a network of Canadian pharmaceutical wholesale and retail businesses, and it has a national network of U.S. distribution centers.
A summary of the business section of the company's latest annual report, filed 8 May 2026.
Company facts
| Ticker | MCK · NYSE |
|---|
| Sector | Distribution |
|---|
| Industry | Health Care Distributors |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 March |
|---|
| Reporting currency | USD |
|---|
| CIK | 927653 |
|---|
| Latest annual report | 10-K, filed 8 May 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Brian S. Tyler | Chief Executive Officer · Director | 28.0K · < 1% | Sale under a 10b5-1 plan, 7 Jul 2026 |
|---|
| Britt J. Vitalone | EVP & CFO | 22.5K · < 1% | Option exercise, 23 May 2026 |
|---|
| LeAnn B. Smith | EVP & Chief HR Officer | 6.6K · < 1% | Sale under a 10b5-1 plan, 1 Jun 2026 |
|---|
| Michele Lau | EVP and Chief Legal Officer | 3.4K · < 1% | Sale under a 10b5-1 plan, 26 May 2026 |
|---|
| Thomas L. Rodgers | EVP, Chief Strategy & BDO | 3.1K · < 1% | Sale under a 10b5-1 plan, 2 Jun 2026 |
|---|
| Dominic J. Caruso | Director | 650 · < 1% | Grant or award, 22 Jul 2026 |
|---|
| Bradley E. Lerman | Director | 301 · < 1% | Open-market sale, 10 Aug 2026 |
|---|
| Maria N. Martinez | Director | 301 · < 1% | Grant or award, 22 Jul 2026 |
|---|
| Kathleen Wilson-Thompson | Director | 301 · < 1% | Grant or award, 22 Jul 2026 |
|---|
| Rutledge Napoleon B JR | SVP, Controller & CAO | — | Sale under a 10b5-1 plan, 8 Sep 2026 |
|---|
| Fraga Francisco | EVP, CIO and CTO | — | Shares withheld for tax, 23 May 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
MCK in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.